NeonMind Engages North Equities for Social Media Marketing Services
NeonMind Engages North Equities for Social Media Marketing Services
Vancouver, B.C. – February 19, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FFE:
6UF) (“NeonMind” or the “Company”) a psychedelic drug development company, is pleased to
announce that it has entered into a 6 month marketing and consulting contract with Toronto‐
based marketing firm, North Equities Corp. (the “Contract”). North Equities specializes in
various social media platforms, and will be able to facilitate greater investor and consumer
engagement and widespread dissemination of the Company’s news.
In addition to press releases, North Equities will be posting important information and updates
through videos from the official NeonMind YouTube channel.
Jason Coles, CEO at North Equites expressed his confidence in North Equities’s ability to create
value for NeonMind stakeholders: “We are very excited to be able to enhance NeonMind
exposure during this significant period in the company’s life cycle. Through our marketing
capabilities on social media platforms, we intend to widen the communication outreach while
providing up to date information about NeonMind to a bigger audience.”
About North Equities
The North Equities team has more than 100 team‐years of equity experience and has helped
more than 200 companies acquire more than 120k+ investors combined. With the perfect
combination of expertise, tactics, and a track record in fundraising and marketing, North
Equities has created the next evolution of investor engagement and marketing.
About NeonMind Biosciences Inc.
NeonMind has two divisions, a consumer products division with a focus on functional
mushroom infused products, and a pharmaceutical division engaged in drug development of
psychedelic compounds. NeonMind’s consumer division currently sells 4 NeonMind branded
coffee products in Canada through NeonMind’s direct to consumer e‐commerce platform. In
its pharmaceutical division, NeonMind’s first drug candidate involves psilocybin (a complex
organic compound found in psychedelic mushrooms) as a treatment for obesity and related
illnesses for which NeonMind is conducting a preclinical trial at the University of British
Columbia. NeonMind’s intellectual property includes methods of aiding in weight loss, treating
compulsive eating disorder, treating obesity and complications of obesity by administering
psilocybin or other psychedelic compounds.
NeonMind’s team includes experts in obesity, psychiatry, psychology, neuroscience, and
intellectual property and executives with experience from leading consumer product and
pharmaceutical companies. Jeff B. Smith, one of NeonMind’s directors, brings more than 20
years of experience, including executive roles such as Company Group Chairman, at Johnson
and Johnson Consumer Companies. Rob Tessarolo, NeonMind’s President and CEO, has 25
years of experience in the pharmaceutical industry and has acted as Chief Executive Officer in
several drug development companies, including Cipher Pharmaceuticals Inc. and Mind
Medicine (Mindmed) Inc. Trevor Millar, NeonMind’s Chief Psychedelic Officer, was formerly the
Chair of MAPS Canada and has extensive experience in the treatment of substance abuse
disorder using psychedelic substances.
For more information on NeonMind, go to www.NeonMindBiosciences.com or buy NeonMind
mushroom infused coffee at www.NeonMind.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416‐750‐3101
Investor Relations:
Edge Communications
Tel: 1‐866‐318‐6874
Renmark Financial Communications Inc.
Melanie Barbeau
Tel: 416‐644‐2020 or 212‐812‐7680
Media Inquiries:
Exvera Communications Inc.
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of
this news release.
Cautionary Statement Regarding Forward‐Looking Statements
Certain statements contained in this press release constitute forward‐looking information. These
statements relate to future events or NeonMind’s future performance. The use of any of the
words "could", "expect", "believe", "will", "projected","estimated" and similar expressions and
statements relating to matters that are not historical facts are intended to identify forward‐
looking information and are based on NeonMind’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may differ materially. In
particular, NeonMind’s drug development plans, its ability to retain key personnel, and its
expectation as to the development of its intellectual property and other steps in its preclinical
and clinical drug development constitute forward‐looking information. Actual results and
developments may differ materially from those contemplated by forward‐looking information.
Readers are cautioned not to place undue reliance on forward‐looking information. The
statements made in this press release are made as of the date hereof. NeonMind disclaims any
intention or obligation to publicly update or revise any forward‐looking information, whether as
a result of new information, future events or otherwise, except as may be expressly required by
applicable securities laws.